Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for prevention of chemotherapy-associated steatosis with FOLFIRI + cetuximab in first-line KRAS wild-type metastatic colorectal cancer
2011-001010-34Phase 2Terminated
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Metformin + FOLFIRI + cetuximab with Placebo + FOLFIRI + cetuximab (2 arms). Primary endpoint: Reduction in chemotherapy-associated steatosis. Started May 2011; status: terminated.
02
Drugs
metformin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-001010-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001010-34.